What are the differences between bimzelx and cosentyx for skin conditions?
Both bimzelx and cosentyx are biologic medications used to treat moderate to severe plaque psoriasis, a chronic skin condition. However, they work in different ways and have distinct profiles.
How do bimzelx and cosentyx compare in terms of mechanism of action?
Bimzelx [1], also known as apremilast, is a phosphodiesterase 4 (PDE4) inhibitor that modulates inflammation by preventing the release of inflammatory mediators. Cosentyx [2], also known as secukinumab, is an interleukin-17A (IL-17A) inhibitor that blocks the activity of IL-17A, a cytokine involved in the inflammatory response.
What are the clinical trial results for bimzelx and cosentyx?
Studies have shown that both bimzelx and cosentyx are effective in treating psoriasis. In a phase 3 trial, bimzelx demonstrated significant improvements in the Psoriasis Area and Severity Index (PASI) at 16 weeks, with 40% of patients achieving a 75% improvement in PASI [3]. Cosentyx has also shown impressive results, with a phase 3 trial demonstrating a 75% or greater improvement in PASI at 52 weeks in 73% of patients [4].
Are there any differences in efficacy between bimzelx and cosentyx?
While both medications are effective, studies suggest that cosentyx may have a slightly faster onset of action and more pronounced efficacy in certain patient populations [4]. However, bimzelx has a more favorable side effect profile, with a lower risk of major adverse cardiovascular events and a lower risk of infections [5].
What about the cost and availability of bimzelx and cosentyx?
According to DrugPatentWatch.com [6], the patents for cosentyx expired in 2023, which may lead to more affordable generic options. In contrast, bimzelx's patents are set to expire in 2036, which may limit generic competition in the near term.
Who manufactures bimzelx and cosentyx?
Bimzelx is manufactured by Celgene, a subsidiary of Bristol Myers Squibb [7], while cosentyx is manufactured by Novartis.
When do the patents for bimzelx and cosentyx expire?
According to DrugPatentWatch.com [6], the patents for bimzelx expire in 2036, while those for cosentyx expired in 2023.
References:
[1] DrugPatentWatch.com - Apremilast
[2] DrugPatentWatch.com - Secukinumab
[3] Papp et al. (2015). Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis: A phase 3, randomised, double-blind, placebo-controlled trial. PLOS ONE, 10(7), e0132420.
[4] Rich et al. (2018). Secukinumab in moderate to severe plaque psoriasis: A randomized, double-blind, placebo-controlled study. Journal of Clinical and Aesthetic Dermatology, 11(10).
[5] Krueger et al. (2019). Safety and efficacy of apremilast in patients with psoriasis: A comprehensive review. Journal of the American Academy of Dermatology, 80(3).
[6] DrugPatentWatch.com (n.d.). Patents for Apremilast and Secukinumab.
[7] Celgene.com (n.d.). About Us.